First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
Titel:
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
Auteur:
Felip, Enriqueta Moreno, Victor Morgensztern, Daniel Curigliano, Giuseppe Rutkowski, Piotr Trigo, José Manuel Calvo, Aitana Kowalski, Dariusz Cortinovis, Diego Plummer, Ruth Maio, Michele Ascierto, Paolo A. Vladimirov, Vladimir I. Cervantes, Andres Zudaire, Enrique Hazra, Anasuya T’jollyn, Huybrecht Bandyopadhyay, Nibedita Greger, James G. Attiyeh, Edward Xie, Hong Calvo, Emiliano